Currently out of the existing stock ratings of Adnan Butt, 50 are a BUY (81.97%), 6 are a HOLD (9.84%), 5 are a SELL (8.2%).

Adnan Butt

Work Performance Price Targets & Ratings Chart

Analyst Adnan Butt works with a stock forecast success ratio of 82.92% fulfilled within 629.13 days on average. Previously, Adnan Butt worked at GUGGENHEIM, RBC.

Adnan Butt’s has documented 102 price targets and ratings displayed on 8 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 22-Feb-2019.

Wall Street Analyst Adnan Butt

Analyst best performing recommendations are on MDCO (THE MEDICINES COMPANY).
The best stock recommendation documented was for MNKD (MANNKIND CORP) at 11/4/2015. The price target of $5 was fulfilled within 62 days with a profit of $9.95 (66.56%) receiving and performance score of 10.73.

Average potential price target upside

of $42.66 (10.2%) on REGN (REGENERON PHARMACEUTICALS).
of $34.87 (249.7%) on ITCI (INTRACELLULAR TH).
of $21.49 (112.59%) on AERI (AERIE PHARMACEUTICALS .).

MDCO The Medicines Company MNKD MannKind Corp OCUL Ocular Therapeutix REGN Regeneron Pharmaceuticals SPPI Spectrum Pharmaceuticals AERI Aerie Pharmaceuticals . ITCI Intracellular Th SGEN Seagen

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Gbola Amusa (CHARDAN CAPITAL)